Pharmaceutical Executive
ClindaReach, from Dusa Pharmaceuticals, offers a simple and practical solution for patients with acne in hard-to-reach places: ClindaReach, an application wand.
REACH BACK
Topin & Associates
BRAND ClindaReach CLIENT Dusa Pharmaceuticals FROM LEFT: John Diaz, vice president, creative director; Michelle Rigot, copywriter
ClindaReach, from Dusa Pharmaceuticals, offers a simple and practical solution for patients with acne in hard-to-reach places: ClindaReach, an application wand.
Dermatologists are used to seeing ads featuring before-and-after photographs of smiling patients. But Dusa asked Topin to push the envelope. "The product is unique, so the client wanted to see something that was really different from other products and ads," says John Diaz, vice president, creative director.
Topin & Associates was charged with creating the launch campaign for the drug and demonstrating—in a simple iconic image—the benefit. But they also added a little humor with an interactive element. The creative produced by the agency first illustrated the hard-to-reach in an amusing way, and then let the audience reveal the ClindaReach solution by lifting a flap on the ad.
According to Diaz, the lighthearted depiction of the problem and visualization of the solution really connected with dermatologists, and created an extremely positive response.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.